Does the POR rs1057868 (A503V) variant reduce adrenal androgen output?

Cytochrome P450 oxidoreductase (POR) is the obligate electron donor for all microsomal cytochrome P450 enzymes. The common POR rs1057868 (A503V, also known as POR*28) polymorphism is a highly frequent, mild hypomorphic variant located in the enzyme's FAD-binding domain.

Mechanistic impact on electron transfer

• In vitro reconstitution assays demonstrate that the POR A503V variant acts as a partial loss-of-function modifier.
• The variant specifically decreases catalytic support to the microsomal steroidogenic enzyme CYP17A1 (17α-hydroxylase/17,20-lyase) to approximately 60% of wild-type levels.
• This reduction in electron delivery is primarily kinetic, decreasing the maximal reaction velocity ($V_{max}$ or $k_{cat}$) of the enzyme complex rather than altering substrate binding affinity ($K_m$).
• In contrast, electron transfer to other microsomal enzymes, such as the 21-hydroxylase CYP21A2, remains largely unaffected, highlighting an enzyme-specific hypomorphic effect.

Impact on adrenal androgen output

• The CYP17A1-catalyzed 17,20-lyase reaction is highly sensitive to electron delivery and represents the first committed, rate-limiting step in adrenal androgen biosynthesis.
• Lowered catalytic efficiency at this step shifts biosynthetic flux, reducing the conversion of 17-hydroxypregnenolone to dehydroepiandrosterone (DHEA) and downstream dehydroepiandrosterone sulfate (DHEA-S).
• While severe loss-of-function POR mutations cause clinical deficiencies, the rs1057868 variant acts as a milder, subclinical modifier that subtly but measurably lowers circulating adrenal androgen levels in susceptible individuals.

Bottom line

• The common POR rs1057868 (A503V) variant is a functional genetic modifier that reduces CYP17A1 catalytic support to roughly 60% of wild-type levels, compromising rate-limiting 17,20-lyase efficiency and contributing to a modest decrease in adrenal androgen output.